Exome Asset Management LLC Makes New $4.10 Million Investment in BioNTech SE (NASDAQ:BNTX)

Exome Asset Management LLC bought a new stake in shares of BioNTech SE (NASDAQ:BNTX - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 34,552 shares of the company's stock, valued at approximately $4,104,000. BioNTech comprises approximately 2.7% of Exome Asset Management LLC's portfolio, making the stock its 10th biggest holding.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Vestcor Inc bought a new stake in BioNTech during the third quarter worth approximately $784,000. Y Intercept Hong Kong Ltd purchased a new position in shares of BioNTech in the 3rd quarter worth approximately $718,000. XTX Topco Ltd bought a new position in shares of BioNTech during the 3rd quarter valued at approximately $459,000. State Street Corp raised its holdings in BioNTech by 2.0% during the 3rd quarter. State Street Corp now owns 155,867 shares of the company's stock valued at $18,512,000 after buying an additional 3,014 shares during the period. Finally, Redmile Group LLC purchased a new position in BioNTech during the third quarter worth $18,345,000. 15.52% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

BNTX has been the subject of several analyst reports. HSBC raised their target price on shares of BioNTech from $97.00 to $136.00 and gave the stock a "buy" rating in a report on Monday, October 7th. Evercore ISI raised BioNTech from an "in-line" rating to an "outperform" rating and upped their target price for the company from $110.00 to $125.00 in a research note on Tuesday, November 19th. HC Wainwright reissued a "buy" rating and set a $150.00 price target on shares of BioNTech in a research note on Monday, November 18th. Bank of America upped their price objective on BioNTech from $125.00 to $150.00 and gave the company a "buy" rating in a research report on Monday, September 16th. Finally, Berenberg Bank began coverage on BioNTech in a research report on Tuesday, November 19th. They set a "buy" rating and a $130.00 target price for the company. Four equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $140.76.

BioNTech Stock Down 0.3 %

BNTX stock traded down $0.31 during trading on Friday, reaching $120.38. 586,070 shares of the company traded hands, compared to its average volume of 808,448. The business has a 50 day simple moving average of $113.86 and a 200 day simple moving average of $100.38. BioNTech SE has a 12 month low of $76.53 and a 12 month high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The company has a market capitalization of $28.62 billion, a price-to-earnings ratio of -57.32 and a beta of 0.22.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.81 EPS for the quarter, topping the consensus estimate of ($1.26) by $2.07. The firm had revenue of $1.24 billion during the quarter, compared to analyst estimates of $514.08 million. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. BioNTech's revenue was up 38.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.73 EPS. On average, equities research analysts anticipate that BioNTech SE will post -3.72 earnings per share for the current fiscal year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.